Issues of etiotropic therapy in conditions of ‘omicron’ strain of SARS-CoV‑2 spreading: Real practice

Abstract

The article presents clinical examples of treatment of patients with COVID-19 diagnosed during the period of active spread of the ‘omicron’ strain. The results of symptomatic therapy and the need for the appointment of etiotropic drugs, including in the late stages of the disease, are considered, which raises the greatest number of questions in clinical practice. In the presented examples, patients received medicines approved by the current temporary guidelines for the diagnosis, treatment and prevention of COVID-19 of the Ministry of Health of the Russian Federation. The analysis of the course of the disease confirms the continuing need for the appointment of etiotropic therapy in the conditions of the spread of the ‘omicron’ variant, including in the second week of the disease. Umifenovir therapy as part of a comprehensive treatment regimen suspends the progression of COVID-19 and leads to relief of symptoms. Symptomatic treatment in the conditions of the spread of a new variant of the coronavirus omicron cannot replace etiotropic and pathogenetic therapy.